How has been the historical performance of Par Drugs & Che.?

Answer:The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.

Breakdown:
Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantly to 119.39 Cr in Mar'25 from 60.12 Cr in Mar'20, with total liabilities also increasing to 119.39 Cr in Mar'25. Cash flow from operating activities was 16.00 Cr in Mar'25, although the net cash outflow was -9.00 Cr, down from a net inflow of 14.00 Cr in Mar'24. Overall, Par Drugs & Che. has shown robust growth in sales and profitability, despite some challenges in cash flow management.